CSF1R inhibitors induce a sex-specific resilient microglial phenotype and functional rescue in a tauopathy mouse model

Noah R. Johnson, Peng Yuan, Erika Castillo, Theresa Lopez, Weizhou Yue, Annalise Bond, Brianna M. Rivera, Miranda C. Sullivan, Masakazu Hirouchi, Kurt Giles, Atsushi Aoyagi, Carlo CondelloNature Communications 2023 · DOI

TL;DR

This study investigates the therapeutic potential of CSF1R inhibitors for tauopathy, a neurodegenerative disease. While these inhibitors reduce tau pathology in both male and female mice, only females show functional recovery and extended survival. This sex-specific benefit is linked to higher drug exposure in males, leading to excitotoxicity and neuroinflammation, suggesting that sex must be considered in developing microglial-targeting therapies.

What Problem Does This Paper Address?

Neurological conditions like Alzheimer's disease and other tauopathies involve microglia, the brain's immune cells, playing a complex role in disease progression. Drugs targeting the colony-stimulating factor-1 receptor (CSF1R) aim to reduce microglial proliferation, a strategy that has shown mixed results in preclinical models. This leaves the therapeutic potential of CSF1R inhibitors unclear. Furthermore, the field has begun to recognize that biological processes, including those in the brain, can exhibit sex-specific differences. This paper addresses the question of whether CSF1R inhibitors can effectively treat tauopathy, and crucially, whether their therapeutic effects and potential side effects differ between male and female mice. The authors aim to define an optimal therapeutic window and explore whether complete microglial ablation is necessary for beneficial outcomes.

Methods

The researchers utilized the Tg2541 mouse model, which develops tau pathology mimicking human tauopathies. They employed two CSF1R inhibitors, PLX3397 and PLX5622, administering them through various dosing paradigms: acute, chronic, and terminal. To assess the impact of the treatment, they used a range of techniques:

  • Tau pathology assessment: Cell-based tau-prion bioassays, ELISA for phosphorylated tau (pTau), and immunohistochemistry (IHC) for tau pathology markers.
  • Microglial depletion: Measured by quantifying microglial markers like Iba1 and P2yr12.
  • Functional outcomes: Assessed through survival analysis, body weight monitoring, and behavioral tests using automated home-cage monitoring systems.
  • Biomarker analysis: Measured plasma levels of neurofilament light chain (NfL), a marker of neuronal injury.
  • Transcriptomic analysis: Utilized Nanostring technology to analyze gene expression patterns in brain tissue, focusing on neuroinflammation, myeloid cell function, and neuropathology.
  • Metabolomics: Employed hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC-MS/MS) to measure neurotransmitter levels (glutamate, GABA).
  • In vivo imaging: Used bioluminescence imaging (BLI) to track astrogliosis.
  • Histopathology: Examined liver tissue for signs of toxicity.

A key methodological aspect was the detailed analysis of sex-specific differences in drug pharmacokinetics, gene expression, and functional outcomes.

Datasets

The study utilized the Tg2541 transgenic mouse model expressing human tau with the P301S mutation. They also used C57BL/6J wild-type mice as controls. No new benchmark datasets were introduced.

Key Insights and Ideas

  • Sex matters, profoundly: The most striking finding is the stark sex-specific difference in therapeutic benefit. While CSF1R inhibition reduces tau pathology in both sexes, only females experience functional rescue and extended survival. This highlights the critical need to consider sex in preclinical research and drug development.
  • Dose-dependent toxicity in males: Higher drug exposure in male mice led to increased immediate early gene (IEG) expression and neurotransmitter dysregulation, suggesting excitotoxicity. This implies that the therapeutic window for CSF1R inhibitors is narrower in males, and excessive dosing can be detrimental.
  • Resilient microglia phenotype: Surviving microglia in treated male mice exhibited a pro-inflammatory gene expression profile, potentially contributing to excitotoxicity. This suggests that not all microglia are equally affected by CSF1R inhibitors, and some may adopt a detrimental phenotype.
  • Complete ablation not necessary: The study demonstrates that significant therapeutic benefits can be achieved without completely eliminating microglia. This is important because microglia have essential homeostatic functions.
  • Tau pathology drives microglial response: The gene expression patterns of microglia were significantly modulated by tau pathology, and CSF1R inhibition differentially affected these tau-activated microglia.

Key Results

  • Tau reduction: CSF1R inhibitors (PLX3397 and PLX5622) significantly reduced tau-prion activity and hyperphosphorylation in Tg2541 mice across various treatment paradigms.
  • Survival extension in females: Terminal treatment with PLX3397 significantly extended the median survival of female Tg2541 mice by 16.5 days (P=0.0004), but had a negligible effect on male survival.
  • Behavioral rescue in females: PLX treatment corrected aberrant hyperactivity in Tg2541 mice, bringing their activity levels closer to wild-type levels, particularly in females.
  • Sex-specific NfL levels: Female treated mice showed reduced plasma NfL (neuronal injury marker), while males showed increased NfL, suggesting PLX-induced toxicity in males.
  • Neurotransmitter dysregulation in males: Male Tg2541 mice treated with PLX showed increased brain glutamate and GABA levels, indicative of excitotoxicity.
  • Gene expression normalization: CSF1R inhibition shifted the gene expression profile of Tg2541 mice towards that of wild-type mice, particularly in non-microglial cells.
  • Sex-specific microglial gene expression: Surviving microglia in male mice showed increased expression of pro-inflammatory genes compared to females.

Limitations and Future Work

  • Mechanism of sex-specific difference: While the study identifies sex-specific differences in drug exposure and downstream effects, the precise underlying molecular mechanisms driving this divergence remain to be fully elucidated.
  • Translational relevance: The study was conducted in mouse models. Further research is needed to confirm these findings in human tauopathies and to optimize dosing strategies for clinical application.
  • OPC involvement: The potential impact of CSF1R inhibitors on oligodendrocyte progenitor cells (OPCs) was noted as an area for future investigation.
  • Intermittent dosing optimization: While intermittent dosing showed promise, further studies are needed to determine the optimal timing and frequency for clinical translation.
  • Combined therapies: The potential synergistic effects of CSF1R inhibitors with tau immunotherapy warrant further exploration.

The authors emphasize the need for careful evaluation of sex in future translational studies of CSF1R inhibitors for tauopathies, and suggest that a nuanced approach, rather than complete microglial ablation, is likely the most effective therapeutic strategy.

Summary updated

Abstract

Microglia are central to pathogenesis in many neurological conditions. Drugs targeting colony-stimulating factor-1 receptor (CSF1R) to block microglial proliferation in preclinical disease models have shown mixed outcomes, thus the therapeutic potential of this approach remains unclear. Here, we show that CSF1R inhibitors given by multiple dosing paradigms in the Tg2541 tauopathy mouse model cause a sex-independent reduction in pathogenic tau and reversion of non-microglial gene expression patterns toward a normal wild type signature. Despite greater drug exposure in male mice, only female mice have functional rescue and extended survival. A dose-dependent upregulation of immediate early genes and neurotransmitter dysregulation are observed in the brains of male mice only, indicating that excitotoxicity may preclude functional benefits. Drug-resilient microglia in male mice exhibit morphological and gene expression patterns consistent with increased neuroinflammatory signaling, suggesting a mechanistic basis for sex-specific excitotoxicity. Complete microglial ablation is neither required nor desirable for neuroprotection and therapeutics targeting microglia must consider sex-dependent effects.
BibTeX
@inproceedings{johnson2023csf,
  author = {Noah R. Johnson and Peng Yuan and Erika Castillo and Theresa Lopez and Weizhou Yue and Annalise Bond and Brianna M. Rivera and Miranda C. Sullivan and Masakazu Hirouchi and Kurt Giles and Atsushi Aoyagi and Carlo Condello},
  title = {{CSF1R inhibitors induce a sex-specific resilient microglial phenotype and functional rescue in a tauopathy mouse model}},
  booktitle = {Nature Communications},
  year = {2023},
  doi = {10.1038/s41467-022-35753-w},
}
Figure